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ABSTRACT 
Regulated trafficking and secretion of insulin by the β cell of the endocrine pancreas is critical to 
maintain our body energy homeostasis. Disruption of these processes typically leads to 
hyperglycemia and the complications of diabetes. Compared to methods using anti-insulin or C-
peptide antibodies, the fluorescent protein labeling approaches provide many advantages in live-
cell, real time format with dynamic spatial and temporal monitoring. Previous studies from our 
lab demonstrated that by fusing a GFP within the C peptide of mouse proinsulin (Ins-C-GFP) 
insulin secretory granule targeting, trafficking and exocytosis could be monitored in live cells. 
Confocal microscopy and western blot results showed over 85% of the Ins-C-GFP can be 
targeted to insulin granules, with highly efficient proteolytic processing to mature insulin and C-
GFP.  
     Our present project aims to establish the minimum molecular determinants within human 
proinsulin required for its targeting to secretory granules.  In order to do this, we designed a viral 
shuttle plasmid containing only the signal peptide, the first 5 residues of the B chain, followed by 
a monomeric GFP(B5), chemically synthesized with restriction sites for highly efficient and 
systematic chimeric and point mutagenesis. Confocal microscopy and 3-D reconstruction 
experiments revealed that the B5 vector was successfully expressed and nearly all of the 
fluorescent protein appeared within the ER(5 transfections; 72 cells), whereas the full-length 
hIns-C-emGFP vector efficiently targets insulin secretory granules. The results make it unlikely 
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that the first five residues of the B chain are sufficient for human proinsulin targeting to secretory 
granules. The results also suggest that the middle of the C peptide is not necessary for human 
proinsulin targeting. We are presently characterizing a construct with the signal peptide alone 
without any insulin B chain residues (B0). By systematically adding back segments from hIns-C-
emGFP to B5 or B0 and the following systematic point mutagenesis, we aim to establish the 
minimal segments and the precise residue(s) or motif(s) of human proinsulin required for 
targeting to secretory granules.  
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1.0  THE IDENTIFICATION OF HUMAN PROINSULIN TRAFFICKING MODULES 
TARGETING INTO INSULIN GRANULE 
Regulated trafficking and secretion of insulin by the β cell of the endocrine pancreas requires 
exquisite coupling of signal flow between stimulus and response and is critical to maintain our 
body energy homeostasis. Disruption of these processes typically leads to hyperglycemia and the 
complications of diabetes. Particularly for peptide hormones, such as insulin, the sites of 
regulation extend from the nucleus to the plasma membrane, with regulated resupply being as 
important as exocytosis of the secretory vesicle. Although the clinical significance of insulin 
secretion disruptions has been widely recognized, the underlying mechanisms regulating its 
targeting into the insulin granule are still unclear. In order to achieve this goal, identification and 
characterization of the multiple subcellular sites, molecular interactions and kinetics of the signal 
flow involved are required.  
Insulin, in mammals, is synthesized in the pancreas within the β-cells of the islets of 
Langerhans. Insulin consists of two polypeptide chains, the A- and B- chains, linked together by 
disulfide bonds. It is however first synthesized as a single polypeptide called preproinsulin in 
pancreatic β-cells. Preproinsulin contains a 24-residue signal peptide which directs the nascent 
polypeptide chain to the rough endoplasmic reticulum (RER). The signal peptide is cleaved as 
the polypeptide is translocated into lumen of the RER, forming proinsulin. In the RER the 
proinsulin folds into the correct conformation and 3 disulfide bonds are formed. About 5–10 min 
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after its assembly in the endoplasmic reticulum, proinsulin is transported to the trans-Golgi 
network (TGN) where immature granules are formed. Transport to the TGN may take about 30 
min(Davidson 2004). 
Proinsulin undergoes maturation into active insulin through the action of cellular 
endopeptidases known as prohormone convertases (PC1 and PC2), as well as the exoprotease 
carboxypeptidase E(Steiner and Oyer 1967). The endopeptidases cleave at 2 positions, releasing 
a fragment called the C-peptide, and leaving 2 peptide chains, the B- and A- chains, linked by 2 
disulfide bonds. The cleavage sites are each located after a pair of basic residues (lysine-64 and 
arginine-65, and arginine-31 and -32), and after cleavage these 2 pairs of basic residues are 
removed by the carboxypeptidase. The C-peptide is the central portion of proinsulin, and the 
primary sequence of proinsulin goes in the order "B-C-A" (the B and A chains were identified on 
the basis of mass and the C-peptide was discovered later)(Davidson 2004).The resulting mature 
insulin is packaged inside mature granules waiting for metabolic signals (such as leucine, 
arginine, glucose and mannose) and vagal nerve stimulation to be exocytosed from the cell into 
the circulation.  
Regulated insulin granule trafficking and exocytosis have been typically measured by 
using insulin antibodies labeled by radioactivity or enzymes, by using capacitance changes, or by 
using amperometry(Watkins, Geng et al. 2002). By far the most popular measure of insulin 
vesicle trafficking and secretion in the basic research lab or clinic is by immunoassays using 
costly I125 radioisotopes or enzymes conjugated to a secondary antibody onto a relatively large-
sized biopsy or perfusate tissue. Though in widespread use, these methods reveal little about the 
underlying molecular and cellular mechanisms at work within the cell. The fluorescent labeling 
approach, however, can study complex molecular and cellular mechanisms underlying regulated 
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secretory peptide vesicle trafficking and exocytosis in a live-cell, real-time format with dynamic 
spatial (subcellular, one-cell, multi-cell, islet) and temporal (millisecond, second, min, to hour) 
monitoring.  
Previously in our lab, we combined confocal and live-cell imaging with a novel 
molecular strategy aimed at revealing mechanisms underlying glucose-regulated insulin vesicle 
secretion(Watkins, Geng et al. 2002). The ‘Ins-C-GFP’ reporter monitors secretory pep- tide 
targeting, trafficking, and exocytosis without directly tagging the mature secreted peptide. We 
trapped a green fluorescent protein (GFP) reporter in equimolar quantity within the secretory 
vesicle by fusing it within the C peptide of proinsulin which only after nascent vesicle sealing 
and acidification is cleaved from the mature secreted A and B chains of insulin. This construct 
provides us great advantage in solving the mystery of how human proinsulin is targeted in β cell.  
1.1 INTRODUCTION 
The “Overall Question” of this project is trying to address is to investigate how human proinsulin 
gets sorted from the TGN into the secretary granule in pancreatic beta cells. The major 
hypothesis for how secretory proteins are sorted to secretory granules postulates the existence of 
membrane receptors (so-called “trans”-element) that bind regulated secretory proteins at the 
level of the trans-Golgi network and direct them to secretory granules.  
Correspondingly, targeting molecules contain a “cis”-element sorting determinant 
ensuring successful delivery.  My over-arching hypothesis is the B chain and/or A chain of 
proinsulin contain(s) the cis-element(s) determining successful delivery into the secretary 
granules. Supporting evidence or assumptions for this model include: 1) mutants in the signal 
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peptide are expected to be excluded because the signal peptide is cleaved from proinsulin and 
does not enter the ER; 2) known ER folding mutants will not exit the ER and therefore are not 
testable candidates for subsequent Golgi to secretory granule sorting(Stoy, Steiner et al. 2010); 
3) C-peptide is excluded for three reasons: the Ins-C-GFP mutants with emGFP inserted in 
proinsulin C peptide was successfully directed into the regulated secretary granules(Watkins, 
Geng et al. 2002); C-peptide sequence is  highly varied among spices, replacement of proinsulin 
C-peptide with hIGF-1 C-peptide does not disrupt the insulin granule targeting(Powell, Orci et 
al. 1988); and various single-chain insulin mutants with a short peptide insertion can also goes 
into the regulated secretary pathway(Groskreutz, Sliwkowski et al. 1994; Rajpal, Liu et al. 2009). 
Finally, there are reports that complete deletion of the C peptide does not prevent proinsulin 
sorting to secretory granules(Powell, Orci et al. 1988; Liu, Ramos-Castaneda et al. 2003). To test 
the hypothesis, we generated mutants of human insulin and evaluating their trafficking in the 
secretion pathway in INS1 cell.  
Figure 1. Secretory proteins can be sorted at either of two levels during secretory granule biogenesis – at the 
trans-Golgi network (TGN) or the immature secretory granule (ISG). 
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Two levels of sorting to the regulated pathway of protein secretion can be distinguished: 
sorting in the trans-Golgi network during the formation of immature secretory granules 
(vesicular intermediates in secretory granule biogenesis), and sorting in the immature secretory 
granules during their maturation(Molinete, Irminger et al. 2000). Proinsulin is processed and 
crystalized in the mature insulin granules. Thus, the properties fitting the mutant that get into the 
TGN but not the SGs---Secreted but not processed or TGN accumulation (little chance because 
of the passive flow for the constitutive secretary pathway). Currently, there are two models in the 
insulin sorting proposed(Arvan and Castle 1998): the receptor-mediated sorting or the 
concentration-dependent sorting. They may coexist in targeting proinsulin into the insulin 
granule. 
One of the limits of previous studies for the intracellular proinsulin trafficking are most 
of them are done in the neuroendocrine cell lines, most in pituitary-derived cell lines, rather than 
the native insulin secreting cell lines which make people question about whether they are 
authentic in the beta cell or insulin secreting cell line derived from them.  
1.2 RESULTS AND DISCUSSION 
In order to identify the Golgi targeting mutation with In-C-emGFP insertion, mutations of N-
terminal half of human proinsulin (B chain + 1-17th amino acids of C peptide) and C-terminal 
half (18-31th amino acids of C peptide and A chain) are made to replace the wide type fragment. 
To achieve this purpose, Nco I - Not I enzyme site pair was used for the N-terminal half while 
Kas I and Hpa I sites for the C-terminal half. To rule out the potential weak dimerization 
between emGFP proteins, the Alanine 206 of the emGFP was substituted with Lysine. 
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Figure 2. Mutating strategies of human proinsulin to identify the trafficking mutants. 
 
Using this strategy, five mutants are chosen to make: the Wakayama, the LA, HisB10Asp 
SerB9Asp and EL-A16/17SA mutants for the following reasons:  
The Wakayama and LA are clinically characterized insulin mutants causing diabetes 
associated with familial hyper-proinsulinemia indicating they may be mis-sorted at TGN into the 
constitutive secretory pathway explaining the hyper-proinsulinemia(Stoy, Steiner et al. 2010).  
The HisB10Asp and SerB9Asp mutants form dimer and monomers only with no further 
polymerization to the hexamers formed by wildtype proinsulin(Brange, Owens et al. 1990). The 
HisB10Asp mutant was reported to be mis-sorted at the Immature Secretory Granules (ISGs) and 
secreted constitutively(Quinn, Orci et al. 1991; Irminger, Vollenweider et al. 1994). These two 
constructs can be used to test/exclude the condensation-dependent sorting model. 
The ELA16/17SA is a mutant reported by the Loh group as constitutively secreted in the 
unprocessed proinsulin form, indicating it is mis-sorted at the TGN(Dhanvantari, Shen et al. 
2003). The paper proposed Carboxypeptidase E(CPE) might be functioning as its potential 
receptor. However, this idea is challenged by subsequent studies: the transgenic CPE-deficient 
CPEfat/fat mouse shows normal insulin processing and secretion(Irminger, Verchere et al. 
1997); How the less abundant receptor CPE can direct proinsulin for its targeting(Thiele, Gerdes 
et al. 1997)?  
My)Vector)Design)for)Casseje)Dele7ons)
B!A!
mP2;emGFP ! ! ! ! !! ! ! !! ! ! ! ! !B5! ! !!
AAA! gAAA! AAA! STOP! VN!
)
Not)I)
)
Ksa)I)
)
Hpa)I)
mIns)II)promoter) mInS)SP) B+C1) emGFP)
Adlox!
C2+A)
AAA! GAA! STOP!VN!
Not)I) Ksa)I) Hpa)I)A206K)
Adlox!p206K!
pInC;emGFP!
Dele<on!Mutants! Systema<c!Point!Mutants!
)
Nco)I)
hInS)SP)
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The C-terminal GFP-tagged proinsulin is also constructed as it was reported only 
partially sorted into the insulin secretary granules (~12%) indicating it does reach the 
TGN(Pouli, Kennedy et al. 1998). We would like to see whether it is processed and secreted 
constitutively or in a regulated (glucose stimulated) manner. 
In order to address these questions, the following mutants were constructed.  
Table 1. Construction of human proinsulin mutants 
Construct/Mutant Constructed Puro Vector Stable cell line Sequenced 
B0 Yes Yes Selecting clones Yes 
B5 Yes No - Yes 
WT Yes Yes Yes Yes 
BC1 Yes - - Yes 
C2A Yes - - Yes 
BCA Yes Yes Selecting clones Yes 
Wakayama Yes Yes In process Yes 
LA Yes No - Yes 
HisB10Asp Yes - - In process 
SerB9Asp Yes - - In process 
A16/17_SerAla In progress - -  
1.2.1 Intracellular Trafficking of Human Proinsulin inside INS-1 Cell. 
First, we made the human proinsulin mutant construct containing peptide only the signal peptide, 
and the first 5 residues of the B chain followed by a monomeric GFP (B5). The first 5 residues of 
the B chain are included to ensure the proper processing and cleavage of the signal peptide when 
the protein translocates into the ER lumen. The restriction sites were chemically synthesized with 
for highly efficient and systematic chimeric and point mutagenesis for the strategy shown in Fig. 
7 and Fig. 8. When this B5 construct was transfected into the INS-1 cell line, it shows the even 
phenotype across the cytoplasm except little black dot (Fig.3). Co-expressing experiment in INS-
1 cells with the B5 and the pInC-mCherry shows these little block spots co-localize with pInC-
mCherry, as shown in lower panel in Fig.3, suggesting they are insulin granule. Compared the 
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B5 with the construct expressing emGFP under the same promoter without signal peptide which 
expressed in the cytosol with clear nucleus, the accumulation of fluorescence inside nucleus 
suggests B5 was, partially at least, expressed in ER. This results shows that the first 5 amino 
acids are insufficient for the human proinsulin molecule to exit ER.  
	  
Figure 3 B5 is insufficient for the insulin granule targeting in INS-1 cell line. A. INS-1 cell was transfected with 
PInsII-emGFP, which is emGFP directly followed with mouse Insulin II promoter. (n=45 from three independent 
transfections.) B. INS-1 cells was transfected with B5 plasmids.(n=52 from four independent transfections.) 
Representative images are shown which were taken at 24hrs post-transfection. Lower panel B5 plasmids was 
transfected into the INS-1 stable cell line expressing Ins-C-mCherry. Images were taken 24 hrs after transfection. 
 
The next question is whether the 5 residues of the B chain are required for the proper 
signal peptide cleavage or not. In order to testify this question, we removed the 5 amino acids 
from the B5 construct by taking advantage of the Not I site pair at both ends of the first 5 amino 
acids of the B chain (B0). As shown in the Fig.4, B0 shows ER accumulation, whose phenotype 
is not dramatically different from the B5. This result suggests that the human proinsulin signal 
peptide is self-competent for properly cleavage without requirement of the involvement of any B 
chain residue.  
pB5:)Deficient)for)ER)Exit)
Ins;C;mCherry ! ! !B5! ! ! !!!!!!Merge!
!!!!!!emGFP! ! !!!!! ! !B5! ! ! ! ! !WT!
!!!B5 ! !!
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Figure 4 B5 does not influence the cleavage of signal peptide of human proinsulin in INS-1 cell line. A. INS-1 
cell was transfected with mProm-emGFP, B5 and B0 constructs, respectively.(n>30) B. INS-1 cells was transfected 
with B5 plasmids(n=21). All images were taken at 24hrs after transfection. 
Then, whether the intact N-terminal half and/or C-terminal half of human proinsulin are 
required for its the proper targeting into the insulin granule or not? To answer this question it, we 
made the constructs contained the B chain and the first 17 amino acids of C peptide (BC1) and 
the following 14 amino acids and A chain (C2A) of human proinsulin. As shown in the Fig.5, 
both BC1 and C2A shows ER accumulation, similar to the phenotype of B5 and B0, suggesting 
that both the N-terminal half and C-terminal half of human proinsulin are required its properly 
intracellular trafficking and β granule targeting.  	  
  
Figure 5 Human proinsulin needs both intact B chain and A chain for its proper targeting into insulin 
granule. INS-1 cell was transfected with B0, BC1 and C2A respectively. (n>30) 
pB0:)The)first)five)AAs)does)not)affect)SP)cleavage))
!!!!mP2;emGFP ! ! ! !!B0! ! ! ! !!!!!!B5!
Ins;C;mCherry ! ! ! !B0! ! ! ! !!!!!Merge!
Half)by)Half:)BC1)Vs)C2A)
B0 ! ! ! ! !BC1 ! ! ! ! !!!C2A !!
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1.2.2 The	  Secretion	  and	  Procession	  of	  Human	  Proinsuin	  
Because	   the	  phenotype	  we	   are	   looking	   for	   is	   the	  Secreted but not processed.	   In	   order	   to	  detect	   this	   phenotype,	  we	  developed	   the	  protocol	   to	   concentrate	   the	  medium	   to	   test	   the	  proinsulin	  presence	  and	  processing	  status	  after	  secretion.	  	  We	   first	   tested	   the	   recovery	   efficiency	   of	   the	   Chloroform/Methanol	   protein	  extraction	  methods	  in	  concentration	  the	  medium	  using	  BSA	  at	  different	  concentration.	  As	  shown	  in	  Fig.6A,	  about	  93%	  of	  BSA	  will	  be	  recovered	  from	  this	  assay.	  We	  performed	  this	  assay	  to	  estimate	  the	  secreted	  fraction	  of	  insulin	  in	  the	  KRBB	  secretion	  buffer	  or	  medium	  at	  resting	   and	   stimulating	   conditions	   (6.5mM	   and	   25mM	   glucose).	   We	   tested	   for	   10mins,	  30mins,	  1hr	  and	  2hr	  for	  stimulation	  and	  30mins	  is	  the	  time	  we	  can	  detect	  the	  insulin	  in	  the	  medium.	  As	  shown	  in	  Fig6.B,	  GFP	  signal	  can	  be	  picked	  up	  in	  the	  medium	  of	  the	  INS-­‐1	  InC-­‐emGFP	  WT	  but	  not	  those	  of	  the	  INS-­‐1	  and	  the	  InC-­‐C96Y	  cell	  lines	  which	  leads	  to	  misfolding	  proinsulin	  with	  ER	  exit	  failure.	  Ins-­‐C-­‐C96Y	  is	  a	  control	  because	  it	  is	  previously	  established	  as	   accumulating	   in	   the	   ER	   with	   little	   if	   any	   secreted	   by	   several	   studies.	   This	   assay	   is	  powerful	  because	  it	  can	  also	  distinguish	  the	  processed	  and	  unprocessed	  fraction	  of	  insulin	  in	  the	  medium.	  In	  the	  lane	  5	  of	  Fig.6B	  or	  6C,	  upper	  band	  is	  proinsulin	  while	  lower	  band	  is	  the	   C-­‐peptide	   with	   emGFP	   insertion	   and	   event	   the	   partially	   processed	   insulin	   is	   also	  observed.	   When	   InC-­‐emGFP	   stable	   lines	   were	   treated	   with	   KRBB	   secretion	   buffer,	   the	  secretion	  fraction	  of	   insulin	  is	  detectable	  at	  30mins(Fig.6C).	  We	  have	  to	  admit	  that	  this	   is	  not	  controlled	  by	  the	  intracellular	  proinsulin	  contents.	  Another	  limit	  for	  this	  method	  is	  the	  final	  detection	  by	  Western	  Blot	  is	  not	  quantitative	  enough	  for	  quantitative	  purpose.	  We	  are	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adapting	   the	  quantification	   step	  by	  with	   fluorescent	   secondary	   antibody	  or	   directly	  with	  ELISA.	  	  
 
Figure. 6. The secretion assay determining the secreted fraction of insulin.  
A. BSA was diluted in a serial concentration and recovered by the Chloroform/Methanol methods.  Recovery rate 
was calculated with three for each condition(Average+/-SD). This was repeated three times.  B. Human insulin 
detected with anti-GFP antibody at the in extracellular medium. Cells are treated with 6.5mM glucose and 25mM for 
2hr stimulation. Medium ware collected at 30min collected for INS-1 InC-emGFP (InC-G) stale cell lines and 
overnight for INS-1, INS-1 InC-C96Y(C96Y) and InC-G stable cell lines was collected overnight. Experience 
repeated three times and reprehensive image are shown here. C. INS-1 InC-emGFP stable cell line is stimulated with 
KRBB secretion buffer containing 25mM glucose. Samples are collected at 0, 10min, 30min, and 2hrs. This 
experiment was repeated three times. 
In order to test for the condensation model or the precise localization of the proinsulin 
molecules, ultrastructural studies using electronic microscopy and subcellular fragmentation 
assays are needed. In order to perform robust secretion assay, over 90% of cell should express 
the mutants. After considering other options, establishing stable cell lines might be our best 
choice. First we find our cell line is resistant to neomycine but not to puromycine. First, we 
engineered our puromycine vector to remove the two Kas I site that will cause problem for our 
future cloning for other fluorescent markers.  Then, we cloned our constructs into the 
puromycine vector. As shown in the Tab. 1,  
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1. For	  B0,	  BCA	  and	  Wakayama	  mutants,	  we	  get	  the	  construct;	  we	  are	  establishing	  the	  stable	  cell	  line	  or	  selecting	  clones.	  2. For	  WT,	  LA	  mutant,	  we	  are	  still	  working	  on	  the	  puromycine	  constructs	  3. For	  the	  HisB10Asp,	  SerB9Asp	  mutants,	  we	  get	  the	  colons	  that	  are	  positive	  at	  double	  digestion	   in	   pAdlox-­‐vector.	   The	   sub-­‐cloning	   into	   the	   puro	   vector	   will	   be	   the	   first	  step.	  	  	  4. For	  ELA16/17SA	  mutant	  is	  stuck	  at	  the	  stage	  of	  construction.	  	  
1.3 FUTURE DIRECTIONS 
In order to test the requirement and the sufficiency of the molecular modules inside human 
proinsulin, more detailed truncation or deletion mutants of the BC1 and C2A will be the next 
step to construct. As shown in Fig.7, the distinction between different constructs indicates the 
requirement or sufficiency role of the human proinsulin fragment in its intracellular trafficking. 
The pInC-em206K, the positive control, targets into the insulin granule as shown in Fig.3 while 
B0, accumulates inside ER. Taking the C-peptide deletion mutant for example. If it shows 
similar phenotype with positive control pInC-em206K, it will suggest that C peptide is not 
required but B chain and A chain are required its proper targeting. If it shows similar phenotype 
with negative control, it will suggest the C peptide is required for the insulin granule targeting. It 
also indicates that C peptide may be sufficient for the proper trafficking inside β cells although it 
requires further evidence by add C peptide into a peptide that does not goes into insulin granule. 
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Figure 7 Strategy for identifying the requirement and sufficiency of molecular modules in human proinsulin 
for its targeting into the insulin granule. Red line indicates requirement while green line indicates sufficiency.  
  
In order to identify the precise residue(s) or motif(s) responsible the ISG targeting, a 
systematic mutation strategy can be utilized to identify the trafficking mutant events, especially 
after the first round of truncation/deletion mutant screening. First, using the random mutagenesis 
to generate a pool of mutations in the potential fragment of human proinsulin such as B chain or 
A chain to replace that fragment in the wide type construct to generate a pool of mutant 
constructs. Then, when then construct has a puromycine selection marker, it can be used to 
generate a stable cell line pool to observe the phenotypic variants under a microscope. When 
certain mis-trafficking phenomenon, such as Golgoi accumulation, is selected by standards of 
live-cell microscopy or the secretion/processing system, the cell line can be sent for genomic 
sequencing with primers starting from the em206K to identify the site mutated to identify the 
mutated residue(s).s 
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Figure 8 Strategy for systematically identification of intracellular trafficking mutants of human proinsulin. 
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2.0  SIDE PROJECTS 
Aside, I also worked on a project on the role of C-peptide relieving the ROS responses induced 
by prolonged high glucose treatment in beta cell.  
2.1.1 C-peptide relieving the high glucose treatment induces ROS response in beta cells. 
Pancreatic beta cells, is among the most ROS-sensitive cells in our body(Rashidi, Kirkwood et 
al. 2009). Briefly, prolonged high glucose treatment stresses beta cells and induces responses in 
ROS generation and beta cell proliferation and eventually death(Bhatt, Lim et al. 2012). C-
peptide, secreted in parallel with insulin has been shown to alleviate the diabetes-associated 
complexities in kidney, eye, brain and blood vessels. This is partially achieved by the decreasing 
ROS generation and its downstream effects in endothelial cells and neural cells. So our question 
is whether C-peptide could play a role in the beta cells by counteracting the effects of high 
glucose-induced ROS responses. Here are our brief results:  1. The	  prolonged	  high	  glucose	  treatment	  in	  INS-­‐1	  cell	  induces	  the	  translocation	  of	  NF-­‐
κB	   from	   the	   cytosol	   into	   the	  nuclear.	  The	   chromatin-­‐associated	   form	   is	   also	   slight	  increased.	  (Fig.	  9A)	  2. The	   treatment	   also	   inhibits	   MAPK	   pathway	   as	   indicated	   by	   the	   lost	   of	   pErk1/2	  signal	  in	  the	  cell	  lysates.	  (Fig.	  9A)	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3. The	  NF-­‐κB	  nuclear	  translocation	  is	  reversed	  when	  C	  peptide	  was	  added	  but	  not	  the	  MAPK	  pathway.	  (Fig.	  9B)	  
   
Figure.9 High glucose induces NFκB nuclear translocation and inhibits MAPK pathway.  
A. INS-1 cell is treated for 72hrs with 5mM, 33mM glucose or alternating between these two concentrations every 
12hrs. Cell lysates was fragmented into cytosolic, nuclear and chromatic fractions. This experiment was repeated 
four times. B. INS-1 cell is treated as in A with or without a serious concentration of C peptide. For testing nuclear 
NFκB, nuclear fraction of cell lysate was used. This experiment is repeated for two times.  
2.1.2 Interaction of Kir6.2 and a-Synuclein at Dopaminergic neurons.  
α-Synuclein has been shown to interact with KATP channel on insulin secretary granule and 
inhibits insulin secretion(Geng, Lou et al. 2011). However, whether it also functions in other 
secretary granule is unknown. Here, I used cell lines derived from the dopaminergic neurons to 
address this question. Here are our brief results: As shown in Fig.10A-C’, α-Synuclein 
colocalizes with KATP channel on the dopamine secretary granule in the dopaminergic neurons. 
Meanwhile, co-immunoprecipitation assay shows it also physically interacts with KATP channel 
(Fig.10D). This interaction can be disturbed by the addition of glibenclimide, a KATP channel 
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opener. These results indicate that α-Synuclein interacts with KATP channel and inhibits its 
functions as in the INS-1 cells. 
 
 
Figure.10 Interaction between KATP channel and a-synuclein on secretary granule in dopaminergic neurons.  
A-C. MND9 cells was treated with 40nM fluorescent Bodipy®TR-glibenclamide (labeling the KATP channel) and 
then stained with anti-α-Synuclein and images taken under confocal microscopy. A’-C’ The subcellular section was 
enlarged to show their localization on the secretary granule. n=40 cells. D. N27 cells lysate was treated with or 
without glibenclamide 250nM and then precipitated with anti-Kir6.2 antibody. This experiment has been repeated 
twice. 
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APPENDIX A 
MATERIALS AND METHODS 
Antibodies and Reagents. 
The following antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and 
used according to provided instructions. Rabbit polyclonal anti-α-synuclein antibody [sc-7011 
(C20)], goat polyclonal anti-α/β-synuclein [sc-7012 (N19)], mouse monoclonal anti-C-peptide 
[sc-57046 (5D3)], goat polyclonal anti-SUR-1 [sc-5789 (C16)], goat polyclonal anti-Kir6.2 [sc-
11226 (N18)], and goat polyclonal anti-Kir6.2 [sc-20809 (H55)]. Alexa fluor 488 goat anti-rabbit 
IgG (H+L), and red fluorescent Bodipy®TR-glibenclamide were from Molecular Probes 
(Invitrogen, Carlsbad, CA).  
 
Cell Culture and Treatment 
Wide type INS1-832/13 cells or INS-1 stably expressing the live-cell fluorescent insulin reporter 
pAd.Ins-C-emGFPwere cultured in d-glucose-free RPMI 1640 medium (GIBCO-BRL) 
supplemented with 10% heat-inactivated fetal calf serum (Bio-Whittaker), 7.5 mM glucose, 10 
mM HEPES, 2 mM l-glutamine, 1 mM sodium pyruvate, 0.05 mM β-mercaptoethanol, 100 
µg/ml streptomycin, and 100 U/ml penicillin in a humidified 5% CO2 incubator at 37°C. MIND9 
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and HT22 cells were cultured in DMEM medium containing 4.5 mg/L glucose, FBS 10% and PS 
(100 U/ml) and incubated at 37°C, 5% CO2. N27 cells in were cultured in RPMI 1640 medium 
containing 4.5 mg/L glucose, FBS 10% and PS (100 U/ml) and incubated at 37°C, 5% CO2. 
Transfections were done with the lipotransfectamine 2000 transfection kit (Invitrogen, Carlsbad, 
CA) according to the manufacture’s manual. 
 
Western Blot and Immunoprecipitation 
Cells were harvested and lysed in radio-immune precipitation assay lysis buffer (Upstate 
Biotechnology) containing protease inhibitor mixture (Sigma). Particulates were cleared by 
centrifugation (10 min, 12,000 g) and the protein concentration of supernatant was determined 
using Bio-Rad protein assay reagent. For immunoprecipitation assay, cell lysate was incubated 
with 1:30, anti-α-synuclein antibody, 610787; BD Transduction Labs; 1:75 anti-Kir6.2 antibody, 
sc-20809 (H55), Santa Cruz; ], overnight at 4 °C on a rotator, followed by the addition of protein 
A/G agarose (Pierce) to the reaction containing specific primary antibody for 2-4 hrs at 4 °C. 
Supernatants were removed and beads were washed 3 times in co-immunoprecipitation buffer 
supplemented with protease inhibitor mixture, complexes were released from the protein A/G 
agarose by boiling for 5 min in 2× SDS-PAGE loading buffer. Western blotting was used to 
detect presence of target proteins in anti-Kir6.2 anti-body [1:1,000; sc-11228 (G16), Santa Cruz] 
or anti-α-synuclein antibody [1:1,000, sc-7011-R (C20), Santa Cruz] in 5% non-fat milk-PBS for 
1 h at room temperature. Blots were washed 4× in PBS containing 0.1% Tween (PBS-T) 
followed by 1 h of incubation, protected from light exposure, in infrared secondary antibodies for 
the appropriate species (Molecular Probes). Signals were detected with ECL reagents 
(Amersham Biosciences). 
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Immunohistochemistry. 
INS1-832/13 cells were fixed with 2% paraformaldehyde in PBS for 20 min, washed in PBS 
three times, and blocked by incubation in 2% BSA in PBS (pH 7.5) overnight at 4°C. The cells 
were then incubated with primary antibodies (as indicated, each at 2 µg/ml) in blocking buffer 
overnight at 4°C. The cells were then washed three times with PBS, incubated with labeled 
secondary antibodies in blocking buffer for 2 hrs at room temperature, and then washed three 
times with PBS. Confocal microscopy was used to detect the immunofluorescence as described 
below.  
 
Confocal fluorescence microscopy. 
Cells were placed into an optical recording chamber (Harvard Apparatus, Holliston, MA) at 
37°C. Single-photon confocal microscopy was performed using an Nikon A10 Confocal live cell 
imaging. Colocalization experiments using two different fluorophores were done by sequential 
excitation and detection of the two channels. Control experiments showed no cross-talk 
detectable under the conditions of the dual-imaging experiments by comparing images from 
sequential acquisition of controls using single fluorophore labeling. Images were recorded 
beginning from the central plane of a cell. Morphometric analysis with NIH imageJ was used to 
localize the fluorescent granules in merged fluorescent images.  
 
Statistical analysis. 
Student's t-test and ANOVA with Bonferroni pairwise posttests were used accordingly to 
evaluate differences. P < 0.05 was considered significant.  
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